mCRPC landscape

This website is intended for UK healthcare professionals only.
 Adverse event reporting information can be found at the bottom of the page.

Home > mCRPC landscape

Prostate cancer is the most common cancer in men living in the UK1

UK map detailing prevalence of prostate cancer
UK map detailing prevalence of prostate cancer

More than 52,000 men are diagnosed with prostate cancer every year on average, with more than 12,000 deaths per year*1
 

A devastating reality for patients with advanced prostate cancer is that it is incurable and often fatal.2,3

*As of August 2023.
 

UK map detailing prevalence of prostate cancer
UK map detailing prevalence of prostate cancer

Living with mCRPC can significantly reduce a patient’s HRQoL due to the worsening
symptoms and adverse events caused by life-prolonging therapies6

Only half of men in the UK with mCRPC will receive more than one line of therapy7

 

Image detailing the declining overall survival as people undergo further lines of treatments
Image detailing the declining overall survival as people undergo further lines of treatments

LYNPARZA is the first PARP inhibitor recommended by NICE and accepted by SMC in mCRPC, available as both monotherapy and in combination with abiraterone and prednisone or prednisolone8-11
 

NICE recommended and SMC accepted as combination therapy for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated8,11
 

NICE recommended and SMC accepted as monotherapy for treating hormone-relapsed mCRPC with BRCA1/2-mutations that has progressed after NHA (such as abiraterone or enzalutamide) in adults9,10
  

Portrait of an older man looking serious
Portrait of an older man looking serious
Two older men standing side by side both looking at the camera
Two older men standing side by side both looking at the camera

Want to know how LYNPARZA works?

Please consult the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

LYNPARZA tablets are indicated as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy, including an NHA.12

LYNPARZA tablets are indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.12

 

References

  1. Prostate Cancer UK. About prostate cancer. Available at: https://prostatecanceruk.org/prostate-information/about-prostate-cancer Accessed June 2024.
  2. Sartor O, et al. N Engl J Med 2018;378:645–657.
  3. Prostate Cancer UK. Advanced prostate cancer. Available at: https://prostatecanceruk.org/prostate-information/just-diagnosed/advanced-prostate-cancer Accessed June 2024.
  4. Prostate Cancer UK. There’s a huge North-South divide in prostate cancer diagnoses. We need your help to change it. Available at: https://prostatecanceruk.org/about-us/news-and-views/2023/01/huge-north-south-divide-in-prostate-cancer-diagnoses Accessed June 2024.
  5. Cancer Research UK. Survival of prostate cancer. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/survival Accessed June 2024.
  6. Holm M, et al. BMC Palliat Care. 2018;17:126.
  7. Leith A, et al. Adv Ther. 2022;39:2236-2255.
  8. Olaparib with abiraterone for untreated hormone relapsed metastatic prostate cancer. NICE TA951. February 2024. Available at https://www.nice.org.uk/guidance/ta951/resources/olaparib-with-abiraterone-for-untreated-hormonerelapsed-metastatic-prostate-cancer-pdf-82615723963333. Accessed June 2024.
  9. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. May 2023. Available at: https://www.nice.org.uk/guidance/ta887/resources/olaparib-for-previously-treated-brca-mutationpositive-hormonerelapsed-metastatic-prostate-cancer-pdf-82613738657221 Accessed June 2024.
  10. Scottish Medicines Consortium. Olaparib (Lynparza). October 2021. Available at: https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-full-smc2366/. Accessed June 2024. 
  11. Scottish Medicines Consortium. Olaparib (Lynparza). March 2024. Available at: https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-mcrpc-full-smc2617/. Accessed June 2024.
  12. LYNPARZA (olaparib). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9204/smpc/ Accessed June 2024.

 

Abbreviations
 

1L=first-line; 2L=second-line; 3L=third-line; HRQoL=health-related quality of life; mCRPC=metastatic castration-resistant prostate cancer; MoA=mode of action; NICE=National Institute for Health and Care Excellence; SMC=Scottish Medicines Consortium.

February 2025 | Job code: GB-64096

Back to top